Atlas Trials

Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

Clinical trial NCT06964815 · RECRUITING

Trial details

NCT number
NCT06964815
Sponsor
Istituto Oncologico Veneto IRCCS
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
GlioblastomaIDH Wild-type and STAT3-positive Glioblastoma
Start date
2025-11-12
Primary completion
2027-10-01
Enrollment
110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.